Hypoxia-inducible factor prolyl hydroxylase inhibition: robust new target or another big bust for stroke therapeutics?

J Cereb Blood Flow Metab. 2012 Jul;32(7):1347-61. doi: 10.1038/jcbfm.2012.28. Epub 2012 Mar 14.


A major challenge in developing stroke therapeutics that augment adaptive pathways to stress has been to identify targets that can activate compensatory programs without inducing or adding to the stress of injury. In this regard, hypoxia-inducible factor prolyl hydroxylases (HIF PHDs) are central gatekeepers of posttranscriptional and transcriptional adaptation to hypoxia, oxidative stress, and excitotoxicity. Indeed, some of the known salutary effects of putative 'antioxidant' iron chelators in ischemic and hemorrhagic stroke may derive from their abilities to inhibit this family of iron, 2-oxoglutarate, and oxygen-dependent enzymes. Evidence from a number of laboratories supports the notion that HIF PHD inhibition can improve histological and functional outcomes in ischemic and hemorrhagic stroke models. In this review, we discuss this evidence and highlight important gaps in our understanding that render HIF PHD inhibition a promising but not yet preclinically validated target for protection and repair after stroke.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Cell Hypoxia / physiology*
  • Enzyme Inhibitors / pharmacology*
  • Humans
  • Hypoxia-Inducible Factor 1 / metabolism*
  • Neuroprotective Agents / pharmacology
  • Procollagen-Proline Dioxygenase / metabolism*
  • Stroke / enzymology*


  • Enzyme Inhibitors
  • Hypoxia-Inducible Factor 1
  • Neuroprotective Agents
  • Procollagen-Proline Dioxygenase